UniQure is a Danish biotech-pharmaceutical company with a portfolio of breakthrough research and products. Just a few months ago, the company’s valuation was once again approaching its all-time high, only to lose 85% over the course of four months. Where does such extreme volatility come from?
Most of the investment thesis currently hinges on a revolutionary therapy with the working name “AMT-130.” It is the first gene therapy of its kind focused on treating Huntington’s disease, an incurable and fatal neurodegenerative disorder.
In its studies, the company showed that the drug can slow disease progression by 60–75%. This would hypothetically mean slowing the disease to a degree that could allow patients to live into old age. In early March, the FDA officially announced that it does not consider the study results to be reliable.
What the FDA expects is a large-scale, long-term, and complex testing and research procedure. However, given the rare and fatal nature of the disease, the requirements set by the FDA range from difficult to meet and unethical, to those that are virtually impossible.
So why the shift in sentiment and an approximately 30% rise in today’s session? The answer lies in the resignation of the head of CBER. Vinay Prasad, strongly linked to the Trump administration and the new U.S. Secretary of Health, Robert F. Kennedy Jr., was dismissed from his position for the second time after months of wreaking havoc on procedures and the decision-making process.
Prasad was personally involved in blocking several promising therapies without substantively addressing the study results.
After Prasad’s departure, the market is betting that the breakthrough therapy, now “in the final stretch,” will return to a path toward rapid market entry.
QURE.US (D1)
Source: xStation5
Morning wrap (05.03.2026)
Iran: Situation overview and outlook
US OPEN: Wall Street buoyed by robust data and shifting sentiment
Daily summary: Markets aren’t afraid of the conflict, valuations are normalizing
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
